In response to growing demand for therapeutic peptides, PolyPeptide Laboratories has announced plans to substantially increase its manufacturing capabilities in both the USA and Europe.
In response to growing demand for therapeutic peptides, PolyPeptide Laboratories has announced plans to substantially increase its manufacturing capabilities in both the USA and Europe.
The expansion will take place at two of PolyPeptide Laboratories's GMP manufacturing facilities: Torrance, California, and Malmo, Sweden.
The result will be a doubling of the manufacturing capacity in Torrance and substantial increases in the capacity in Malmo.
The expansion plans for both facilities focus mainly on increased capacity for solid-phase peptide manufacturing.
The increase in solid-phase capacity in the Torrance and Malmo facilities serves to complement the large solution-phase synthesis capabilities already present at the PolyPeptide Laboratories facilities in Malmo, Sweden and Hillerod, Denmark.
The decision to expand the facilities in response to the increasing demand from both biotech and pharmaceutical customers for experienced large-scale GMP peptide manufacturing will help to maintain PolyPeptide Laboratories's leading position in this market, the company believes.
The combination of technical know-how, state-of-the-art production facilities and comprehensive regulatory support that PolyPeptide laboratories provides its customers is considered a critical advantage in the competitive drug development arena, and has helped to sustain double digit growth rates for the company, it says.
Both biotech and large pharmaceutical companies have benefited from the experience and knowledge of PolyPeptide Laboratories in the development of their clinical peptide therapeutic compounds.
The new facilities are planned to begin production in 2006.
PolyPeptide Laboratories is a privately owned group of companies focused exclusively on the manufacture of active pharmaceutical ingredients based on peptides.
PolyPeptide Laboratories manufactures both proprietary and generic peptides for the pharmaceutical industry.
